Monoclonal antibody · developed by Genmab
GEN1107 is a drug studied in endometrial cancer, ovarian cancer, triple negative breast cancer, gastroesophageal cancer, non-small cell lung cancer, and urothelial carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06171789 | Phase 1/2 | Endometrial Cancer | Terminated | GMAB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Endometrial CancerGastroEsophageal CancerNon-small Cell Lung CancerOvarian CancerTriple Negative Breast CancerUrothelial Carcinoma
See GMAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GMAB catalysts and pipeline →